Omeros corporation to announce fourth quarter and year-end financial results on march 1, 2022

Seattle--(business wire)--omeros corporation (nasdaq: omer) today announced that the company will issue its fourth quarter and year-end financial results for the period ended december 31, 2021, on tuesday, march 1, 2022, after the market closes. omeros management will host a conference call and webcast that day at 4:30 p.m. eastern time (1:30 p.m. pacific time) to discuss the financial results as well as recent developments and highlights. conference call details to access the live conference call via phone, please dial (844) 831-4029 from the united states and canada or (920) 663-6278 internationally. the participant passcode is 2686968. please dial in approximately 10 minutes prior to the start of the call. a telephone replay will be available for one week following the call and may be accessed by dialing (855) 859-2056 from the united states and canada or (404) 537-3406 internationally. the replay passcode is 2686968. to access the live and subsequently archived webcast of the conference call, go to omeros’ website at https://investor.omeros.com/upcoming-events. about omeros corporation omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases) and cancers. omeros’ lead masp-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application pending before fda for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including iga nephropathy, atypical hemolytic uremic syndrome and covid-19. oms906, omeros’ inhibitor of masp-3, the key activator of the alternative pathway of complement, is in a phase 1 clinical trial. for more information about omeros and its programs, visit www.omeros.com.
OMER Ratings Summary
OMER Quant Ranking